Compare DexCom, Inc. (DXCM) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs National Beverage Corp. — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while National Beverage Corp. trades at $30.9 (market cap $2.89B). The key difference: DexCom, Inc. is far larger — about 11.7× National Beverage Corp.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| DXCM | FIZZ | |
|---|---|---|
Market Cap | $33.79B | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $46.75 |
52-Week Low | $54.84 | $30.53 |
Enterprise Value | $33.24B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
FIZZ trades at $30.95, down 0.29% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. Revenue has been stable around $1.2B annually, with net income margins improving to 15.56% in 2025. Recent earnings have missed expectations in three of the last four quarters, while the company declared a special dividend of $3.25 per share payable in July 2026.
The outlook is mixed; strong profitability and a reasonable P/E of 15.73 offer value, but stagnant growth and bearish analyst consensus pose risks. The stock's performance hinges on reversing earnings misses and addressing competitive pressures in the beverage market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
